Botulinum toxin type B for treatment of axillar hyperhidrosis

被引:65
作者
Dressler, D
Saberi, FA
Benecke, R
机构
[1] Univ Rostock, Dept Neurol, D-18147 Rostock, Germany
[2] Klinikum Nord, Botulinum Toxin Clin, Dept Neurol, Hamburg, Germany
关键词
botulinum toxin type B; therapy; axillar hyperhydrosis; conversion factor;
D O I
10.1007/s00415-002-0929-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, botulinum toxin type B (BT-B) became commercially available for treatment of cervical dystonia. It is the aim of this study to explore its use for treatment of bilateral axillar hyper-hydrosis (HH). For this we directly compared the antihyperhydrotic effect of BTB (NeuroBloc(R)/MyoBloc(TM)) with that of botulinum toxin type A (BT-A) (Botox(R)). 9 patients (HD group) received BT-A 100MU unilaterally and BT-B 4000MU contralaterally. 10 patients (LD group) received BT-A 100MU and BT-B 2000MU All patients were blinded as to which preparation was used in which side. All patients except one reported excellent HH improvement in both axillae. None of the patients had residual HH on clinical examination. The duration of HH improvement until first recurrence in the HD group was 16.0 +/- 4.3 weeks in the BT-A treated axillar and 16.4 +/- 4.5 weeks in the BT-B treated axillae (Wilcoxon rank-sum test, p = 0.336). In the LD group it was 16.4 +/- 5.3 weeks in the BT-B treated axillae and 17.1 +/- 5.7 weeks in the BT-A treated axillae (Wilcoxon rank-sum test, p = 0.059). There was also no difference in the duration of HH improvement between the axillae treated with BT-B 4000MU and BT-B 2000MU (Wilcoxon rank-sum test, p = 0.712). 5 out of 9 patients in the HD group (chi-square test, p = 0.025) and 7 out of 10 patients in the LD group (chi-square test, p = 0.008) reported more application discomfort in the BT-B treated axillae. In 6 out of 9 patients in the HD group (chi-square test, p = 0.014) and in 6 out of 10 patients in the LD group (chi-square test, p = 0.014) the onset of HH improvement appeared earlier in the BT-B treated axillae. One patient in the HD group reported dryness of the mouth and eyes and accomodation difficulties. BT-B is a safe and efficient treatment for axillar HH. Doses of BT-B 2000MU per axilla seem sufficient indicating a conversion factor between BT-A and BT-B in the order of 1:20. With a conversion factor for cervical dystonia in the order of 1:40 the autonomic nervous system seems to be relatively more sensitive to BT-B than to BT-A compared with the motor system.
引用
收藏
页码:1729 / 1732
页数:4
相关论文
共 50 条
  • [31] The clinical profile of Elan Pharmaceuticals' botulinum toxin type B
    O'Brien, CF
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 : 13 - 17
  • [32] Bladder Paralysis Due to Foodborne Botulinum Toxin Type B
    Loiseau, Karine
    Scheiber-Nogueira, Maria-Carmelita
    Tilikete, Caroline
    Vighetto, Alain
    Rode, Gilles
    UROLOGY JOURNAL, 2010, 7 (01) : 63 - 65
  • [33] Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure (vol 250, pg 967, 2003)
    Dressler, D
    Bigalke, H
    Benecke, R
    JOURNAL OF NEUROLOGY, 2003, 250 (10) : 1263 - 1265
  • [34] Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F
    Roberto Eleopra
    Valeria Tugnoli
    Rocco Quatrale
    Ornella Rossetto
    Cesare Montecucco
    Dirk Dressler
    Neurotoxicity Research, 2006, 9 : 127 - 131
  • [35] Clinical use of non-A botulinum toxins: Botulinum toxin type C and botulinum toxin type F
    Eleopra, Roberto
    Tugnoli, Valeria
    Quatrale, Rocco
    Rossetto, Ornella
    Montecucco, Cesare
    Dressler, Dirk
    NEUROTOXICITY RESEARCH, 2006, 9 (2-3) : 127 - 131
  • [36] Hailey-Hailey disease treatment with Botulinum toxin type A
    Bessa, Giancarlo Rezende
    Grazziotin, Thais Corsetti
    Manzoni, Ana Paula
    Weber, Magda Blessmann
    Bonamigo, Renan Rangel
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2010, 85 (05) : 717 - 722
  • [37] Botulinum toxin type A in pregnancy
    Tan, Michael
    Kim, Eunji
    Koren, Gideon
    Bozzo, Pina
    CANADIAN FAMILY PHYSICIAN, 2013, 59 (11) : 1183 - 1184
  • [38] BotB (botulinum toxin type B), evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)
    Truong, DD
    Cullis, PA
    OBrien, CF
    Koller, M
    Villegas, TP
    Wallace, JD
    MOVEMENT DISORDERS, 1997, 12 (05) : 772 - 775
  • [39] Botulinum, Toxin Type B clinical safety in cervical dystonia following up to 4 years of treatment
    Birmingham, William
    Pappert, Eric
    Salazar-Grueso, Edgar
    TOXICON, 2008, 51 : 24 - 24
  • [40] Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin
    Eriksson Mirkovic, Sandra
    Rystedt, Alma
    Balling, Mie
    Swartling, Carl
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 (01) : 103 - 107